What Is the Future of the Gastrointestinal Therapeutics Market? Growth Forecasts
According to a newly published market research report by 24LifeSciences, global gastrointestinal therapeutics market is valued at USD 35,410 million in 2026 and is projected to reach USD 51,860 million by 2034, growing at a compound annual growth rate (CAGR) of 5.7% during the forecast period.
Gastrointestinal therapeutics comprise a critical class of pharmaceuticals designed to treat a wide range of disorders affecting the digestive system, from the esophagus to the colon. This includes prevalent conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and inflammatory bowel disease (IBD). The therapeutic arsenal includes well-established drugs like proton pump inhibitors, biologics, and antacids, commercially available under brands such as Aciphex (rabeprazole) and Prilosec (omeprazole). The sustained efficacy and expanding applications of these treatments continue to underpin their importance in both primary care and specialized gastroenterology practice.
Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/8881/gastrointestinal-therapeutics-marketWhat Is the Future of the Gastrointestinal Therapeutics Market? Growth Forecasts
According to a newly published market research report by 24LifeSciences, global gastrointestinal therapeutics market is valued at USD 35,410 million in 2026 and is projected to reach USD 51,860 million by 2034, growing at a compound annual growth rate (CAGR) of 5.7% during the forecast period.
Gastrointestinal therapeutics comprise a critical class of pharmaceuticals designed to treat a wide range of disorders affecting the digestive system, from the esophagus to the colon. This includes prevalent conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and inflammatory bowel disease (IBD). The therapeutic arsenal includes well-established drugs like proton pump inhibitors, biologics, and antacids, commercially available under brands such as Aciphex (rabeprazole) and Prilosec (omeprazole). The sustained efficacy and expanding applications of these treatments continue to underpin their importance in both primary care and specialized gastroenterology practice.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8881/gastrointestinal-therapeutics-market
